This content is protected against AI scraping.
On April 18, 2026, President Donald Trump used an executive order signing ceremony focused on psychedelic research to push his administration for progress on cannabis rescheduling. While the event’s primary purpose was to accelerate medical research into substances like ibogaine for treating severe mental illness and veteran PTSD, Trump took the opportunity to publicly question why his December order to reclassify cannabis as a Schedule III drug was being “slow-walked.” The inquiry was notably made in the presence of podcaster Joe Rogan and high-ranking health officials, including HHS Secretary Robert F. Kennedy Jr.
The delay in cannabis rescheduling appears tied to recent leadership shifts at the Department of Justice. Following the removal of Pam Bondi, the responsibility now falls to Acting Attorney General Todd Blanche. While Blanche has expressed a commitment to “careful consideration” and coordination with the DEA, he has yet to take definitive action.
This is a summary. Read the original article here.
Original article written by Tony Lange. Published on April 20, 2026 by Cannabis Business Times.
